Description: This session from the 1995 SOA Vancouver Meeting covers the impact on insurance companies from rating, the different rating agencies, the varying processes and information used by the rating agencies and criticism of rating agencies. It also covers information from A.M. Best. From the Record of the Society of Actuaries, Vol. 21, No. 3b.

Description: This session from the 1995 SOA Vancouver Meeting discusses assumptions for pension valuation including rates of termination, retirement, disability and mortality. Also addressed is the SOA Pension Section Council's research on rates of termination and the new mortality tables. From the Record of the Society of Actuaries, Vol. 21, No. 3b.

Description: A discussion by several experts of reform activity at the state level will be included. What can be learned from reforms to date? What is likely to happen in the near term? From the Record of the Society of Actuaries, Vol. 21, No. 3b.

Description: This session from the 1995 SOA Boston Meeting examines the regulatory process, how an idea for a model bill works its way through the NAIC, the function of the ACLI and how from an industry side the process can be influenced at the state and federal levels. From the Record of the Society of Actuaries, Vol. 21, No. 4a.

Description: This session from the 1995 SOA Boston Meeting Panelists will review the Canadian experience in adopting dynamic solvency testing DST and the impact of DST on how companies do business, changes which have been made and the changes suggested to the DST. From the Record of the Society of Actuaries, Vol. 21, No. 4a.

Description: This session from the 1995 SOA Boston Meeting presents different governmental approaches to providing financial security and health benefits for retirees, the problems associated with aging populations and the reduction in resources available to meet their needs. From the Record of the Society of Actuaries, Vol. 21, No. 4a.

Description: One important lesson learnt from the recent financial crisis was that overreliance on financial models could lead to unforeseen and harmful consequences. Model risk management (MRM) is becoming a core and mandatory component in enterprise risk management for many financial institutions, especially Fed/OCC CCAR-compliant firms. In recent years, insurance companies are also being required to have model risk management programs by Solvency II, ORSA and other supervisory guidance. MRM is not just model validation. It consists of governance and policies regarding a model's life cycle including data, model development, model test and implementation, model validation, model monitoring and documentation. It also provides guidelines and standards for risk assessment and model inventory management. The presenters will discuss current and best practice MRM, approach for model validation and auditing, as well as topics for technical issues such as types of model risks. It will also discuss the differences between Fed/OCC standards and Solvency II standards. At the conclusion of the session, attendees will be able to: Describe best practice in model risk management; Explain requirements and standards; and Develop model validation procedure.

Description: This session provides actuaries who work with group life and disability products with the opportunity to participate in a moderated discussion with their colleagues. The specific topics will be those of interest to attendees, but are likely to include recent experience trends, product development, pricing and reserving.

Description: This session describes the process payers and employers can use to evaluate emerging medical device technologies, recent or pending FDA submissions for prescription drugs and experimental treatments that impact patient care, resource utilization and health care expenditures. We will walk through the process of identifying and selecting impactful treatments (Horizon Scanning) and quantifying the financial cost of new technologies before they arrive in the market. These workflows can be leveraged by actuaries, healthcare economists, clinicians and pharmacists from a payer (Commercial and Medicare) and employer perspective for self-funded plans. We will also walk through some sample models that illustrate how costs for emerging technologies and treatments can be modeled.

Description: In this presentation, the authors develop a stochastic generator for the generation of scenarios of the S & P 500 index, dividend yield, consumer price index, and U.S. Treasury yields. They first create a set of 'stylized facts' for these series. These in-sample statistical models are themselves not suitable for generation of scenarios for decision making, but instead are additional stylized facts that assist in model development. The 'best' statistical model according to standard statistical model selection criteria can easily lead to a model that is highly unsuitable for generation of scenarios for decision making. The authors develop a stochastic generator that is suitable for decision making under uncertainty. From Actuarial Research Clearing House 1997, Vol. 1.